RxDoctor Payments Data

Casey Turnbough

Psychiatric/Mental Health · Portales, NMNPI 1962719849

Payments from drug & device makers

$659in general payments, 2019–2025

Across 29 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$292
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
  • Axsome Therapeutics, Inc.$52
  • Neurocrine Biosciences, Inc.$43
  • Supernus Pharmaceuticals, Inc.$30
  • Teva Pharmaceuticals USA, Inc.$25
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$61293%
  • Education$477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$659 in reported general payments places this provider in the 70th percentile of 228 psychiatric/mental health providers in New Mexico.

See all psychiatric/mental health providers in New Mexico

Medicare billing

Part B allowed, 2024
$39,219
Medicare patients
37
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate11$18,127
Lurasidone Hcl21$5,406
Divalproex Sodium ErDivalproex Sodium35$2,068
Duloxetine Hcl86$1,025
Doxepin Hcl17$844
Quetiapine Fumarate ErQuetiapine Fumarate60$496
Haloperidol12$477
Hydroxyzine Pamoate17$420
Gabapentin108$371
Aripiprazole42$371
Olanzapine18$308
Sertraline Hcl41$301
Hydroxyzine Hcl21$296
Paroxetine Hcl23$292
Quetiapine Fumarate59$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$150$18,12711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 228 psychiatric/mental health providers in New Mexico.

Other psychiatric/mental health in Portales

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →